-
1
-
-
77949932021
-
-
U. S. C. §§ 360aa-360ee (2004).
-
(2004)
U. S. C.
, vol.21
-
-
-
2
-
-
77949963258
-
Medical liability for pharmacogenomics, pharmacogenomics: Social
-
Mark A. Rothstein ed
-
Larry I. Palmer, Medical Liability for Pharmacogenomics, Pharmacogenomics: Social, Ethical, and Clinical Dimensions (Mark A. Rothstein ed., 2003).
-
(2003)
Ethical, and Clinical Dimensions
-
-
Palmer, L.I.1
-
6
-
-
77950016228
-
-
supra note 3, at
-
Owen, supra note 3, at 564.
-
-
-
Owen1
-
7
-
-
77949948091
-
-
Id. at
-
Id. at 853.
-
-
-
-
8
-
-
77949966390
-
Epilogue: Policy prescriptions, pharmacogenomics: Social
-
Mark A. Rothstein ed
-
Mark A. Rothstein, Epilogue: Policy Prescriptions, Pharmacogenomics: Social, Ethical, and Clinical Dimensions 327 (Mark A. Rothstein ed., 2003).
-
(2003)
Ethical, and Clinical Dimensions
, pp. 327
-
-
Rothstein, M.A.1
-
9
-
-
77949979403
-
The gradual enfeeblement of the learned intermediary rule and the argument in favor of abandoning it entirely
-
James O. Castagnera et al., The Gradual Enfeeblement of the Learned Intermediary Rule and the Argument in Favor of Abandoning It Entirely, 36 Tort & Ins. L. J. 119 (2000-2001).
-
(2000)
Tort & Ins. L. J.
, vol.36
, pp. 119
-
-
Castagnera, J.O.1
-
10
-
-
0043104744
-
When drugs are safer for some but not others: The FDA experience and alternatives for products liability
-
Margaret Gilhooley, When Drugs Are Safer for Some But Not Others: The FDA Experience and Alternatives for Products Liability, 36 Hou. L. Rev. 927, 939 (1999).
-
(1999)
Hou. L. Rev.
, vol.36
, Issue.927
, pp. 939
-
-
Gilhooley, M.1
-
11
-
-
77949974337
-
-
Food and Drug Administration, Final Guidance on Direct-to-Consumer Advertising, Fed. Reg
-
Food and Drug Administration, Final Guidance on Direct-to-Consumer Advertising, 64 Fed. Reg. 43, 197 (1999).
-
(1999)
, vol.64
, Issue.43
, pp. 197
-
-
-
12
-
-
77949923566
-
-
Food and Drug Administration, Report to Congress on Postmarketing Studies, available at
-
Food and Drug Administration, Report to Congress on Postmarketing Studies (2003), available at www.fda.gov/cber/fdama/pstmrktfdamal30.htm.
-
(2003)
-
-
-
13
-
-
0042855876
-
Ethical, legal and social implications of genetic medicine
-
Ellen Wright Clayton, Ethical, Legal and Social Implications of Genetic Medicine, 349 New Eng. J. Med. 562 (2003).
-
(2003)
New Eng. J. Med.
, vol.349
, pp. 562
-
-
Clayton, E.W.1
-
14
-
-
0031911191
-
-
ASHG Social Issues Subcommittee on Familial Disclosure, Professional Disclosure of Familial Genetic Information
-
ASHG Social Issues Subcommittee on Familial Disclosure, Professional Disclosure of Familial Genetic Information, 62 Am. J. Hum. Genet. 474 (1998).
-
(1998)
Am. J. Hum. Genet.
, vol.62
, pp. 474
-
-
-
15
-
-
77950007292
-
-
C. F. R. pts. 160
-
C. F. R. pts. 160, 164 (2005).
-
(2005)
, vol.45
, pp. 164
-
-
-
17
-
-
77950018989
-
Doctors debate use in tests of safer but costlier dyes
-
Dec. 2
-
Frank E. James, Doctors Debate Use in Tests of Safer but Costlier Dyes, Wall St. J., Dec. 2, 1988.
-
(1988)
Wall St. J.
-
-
James, F.E.1
|